Silo Pharma Aligns PTSD Drug with Federal Psychedelics Push
Event summary
- President Trump signed an executive order on April 18, 2026, accelerating psychedelic therapy research, aligning with Silo Pharma's SPC-15 PTSD program.
- SPC-15 is an intranasal serotonin 4 (5-HT4) receptor agonist targeting prophylactic PTSD treatment.
- The program leverages a 505(b)(2) regulatory pathway for potentially streamlined development.
- Silo Pharma is preparing for IND engagement with the FDA for SPC-15.
The big picture
The federal push to fast-track psychedelic therapies creates a strategic advantage for Silo Pharma's SPC-15 program, positioning it to capitalize on growing acceptance of novel mental health treatments. The company's focus on intranasal drug delivery and IP-backed approaches aligns with broader industry trends toward optimized CNS therapeutics. The global mental health market's expansion further amplifies the potential impact of Silo Pharma's pipeline.
What we're watching
- Regulatory Tailwinds
- How the federal executive order will accelerate FDA approval timelines for psychedelic-based therapies like SPC-15.
- Market Opportunity
- Whether the expanding mental health therapeutics market can sustain Silo Pharma's commercial prospects.
- Execution Risk
- The pace at which Silo Pharma can advance SPC-15 through clinical trials and regulatory milestones.